Tags

Type your tag names separated by a space and hit enter

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma.
Ann Allergy Asthma Immunol. 2002 Feb; 88(2):227-35.AA

Abstract

BACKGROUND

Asthma is a chronic disease characterized by inflammation and bronchoconstriction. Medications that are able to effectively treat both components are advantageous.

OBJECTIVE

To compare the efficacy of an inhaled corticosteroid and a long-acting beta2-agonist combination product with a leukotriene antagonist for initial maintenance therapy in patients who were symptomatic while receiving short-acting beta2-agonists alone.

METHODS

A 12-week, randomized, double-blind, double-dummy, multicenter study was conducted in 432 patients 15 years of age and older with persistent asthma who were symptomatic on short-acting beta2-agonists alone. Fluticasone propionate 100 microg and salmeterol 50 microg combination product (FSC) twice daily or montelukast 10 mg once daily was administered.

RESULTS

At endpoint, compared with montelukast, FSC significantly increased morning predose forced expiratory volume in 1 second (0.61 +/- 0.03 L vs 0.32 +/- 0.03 L), morning peak expiratory flow rate (peak expiratory flow rate; 81.4 +/- 5.9 L/minute vs 41.9 +/- 4.8 L/minute), evening peak expiratory flow rate (64.6 +/- 5.3 L/minute vs 38.8 +/- 4.7 L/minute), the percentage of symptom-free days (40.3 +/- 2.9% vs 27.0 +/- 2.7%), the percentage of rescue-free days (53.4 +/- 2.8% vs 26.7 +/- 2.5%), and the percentage of nights with no awakenings (29.8 +/- 2.5% vs 19.6 +/- 2.1%) (P < or = 0.011, all comparisons). At endpoint, FSC significantly reduced asthma symptom scores (-1.0 +/- 0.1 vs -0.7 +/- 0.1) and rescue albuterol use (-3.6 +/- 0.2 puffs/day vs -2.2 +/- 0.2 puffs/day) compared with montelukast (P < 0.001). At endpoint, patients treated with FSC also had a significantly greater improvement in quality of life scores and were more satisfied with their treatment compared with montelukast-treated patients (P < or = 0.001). Both treatments were well tolerated.

CONCLUSIONS

Initial maintenance therapy with FSC provides greater improvement in asthma control and patient satisfaction than montelukast.

Authors+Show Affiliations

Colorado Allergy and Asthma Centers, PC, Denver 80230, USA. ds.pearlman@coloradoallergy.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11868930

Citation

Pearlman, David S., et al. "Fluticasone Propionate/salmeterol Combination Compared With Montelukast for the Treatment of Persistent Asthma." Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, vol. 88, no. 2, 2002, pp. 227-35.
Pearlman DS, White MV, Lieberman AK, et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol. 2002;88(2):227-35.
Pearlman, D. S., White, M. V., Lieberman, A. K., Pepsin, P. J., Kalberg, C., Emmett, A., Bowers, B., Rickard, K. A., & Dorinsky, P. (2002). Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 88(2), 227-35.
Pearlman DS, et al. Fluticasone Propionate/salmeterol Combination Compared With Montelukast for the Treatment of Persistent Asthma. Ann Allergy Asthma Immunol. 2002;88(2):227-35. PubMed PMID: 11868930.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. AU - Pearlman,David S, AU - White,Martha V, AU - Lieberman,Allen K, AU - Pepsin,Pamela J, AU - Kalberg,Chris, AU - Emmett,Amanda, AU - Bowers,Brian, AU - Rickard,Kathleen A, AU - Dorinsky,Paul, PY - 2002/3/1/pubmed PY - 2002/3/26/medline PY - 2002/3/1/entrez SP - 227 EP - 35 JF - Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology JO - Ann Allergy Asthma Immunol VL - 88 IS - 2 N2 - BACKGROUND: Asthma is a chronic disease characterized by inflammation and bronchoconstriction. Medications that are able to effectively treat both components are advantageous. OBJECTIVE: To compare the efficacy of an inhaled corticosteroid and a long-acting beta2-agonist combination product with a leukotriene antagonist for initial maintenance therapy in patients who were symptomatic while receiving short-acting beta2-agonists alone. METHODS: A 12-week, randomized, double-blind, double-dummy, multicenter study was conducted in 432 patients 15 years of age and older with persistent asthma who were symptomatic on short-acting beta2-agonists alone. Fluticasone propionate 100 microg and salmeterol 50 microg combination product (FSC) twice daily or montelukast 10 mg once daily was administered. RESULTS: At endpoint, compared with montelukast, FSC significantly increased morning predose forced expiratory volume in 1 second (0.61 +/- 0.03 L vs 0.32 +/- 0.03 L), morning peak expiratory flow rate (peak expiratory flow rate; 81.4 +/- 5.9 L/minute vs 41.9 +/- 4.8 L/minute), evening peak expiratory flow rate (64.6 +/- 5.3 L/minute vs 38.8 +/- 4.7 L/minute), the percentage of symptom-free days (40.3 +/- 2.9% vs 27.0 +/- 2.7%), the percentage of rescue-free days (53.4 +/- 2.8% vs 26.7 +/- 2.5%), and the percentage of nights with no awakenings (29.8 +/- 2.5% vs 19.6 +/- 2.1%) (P < or = 0.011, all comparisons). At endpoint, FSC significantly reduced asthma symptom scores (-1.0 +/- 0.1 vs -0.7 +/- 0.1) and rescue albuterol use (-3.6 +/- 0.2 puffs/day vs -2.2 +/- 0.2 puffs/day) compared with montelukast (P < 0.001). At endpoint, patients treated with FSC also had a significantly greater improvement in quality of life scores and were more satisfied with their treatment compared with montelukast-treated patients (P < or = 0.001). Both treatments were well tolerated. CONCLUSIONS: Initial maintenance therapy with FSC provides greater improvement in asthma control and patient satisfaction than montelukast. SN - 1081-1206 UR - https://www.unboundmedicine.com/medline/citation/11868930/Fluticasone_propionate/salmeterol_combination_compared_with_montelukast_for_the_treatment_of_persistent_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1081-1206(10)62001-7 DB - PRIME DP - Unbound Medicine ER -